Table 1.
Baseline characteristics of the patients.
| Total (n = 94) | APOBEC3B Low * (n = 23) | APOBEC3B High ** (n = 71) | p-Value | ||
|---|---|---|---|---|---|
| Age | median (range) | 68 (36–93) | 68 (48–88) | 70 (36–93) | |
| <65 | 33 | 6 | 27 | 0.297 | |
| ≥65 | 61 | 17 | 44 | ||
| Sex | Female | 22 | 5 | 17 | 0.828 |
| Male | 72 | 18 | 54 | ||
| ECOG-PS *** | 0 | 16 | 1 | 15 | |
| 1 | 23 | 5 | 18 | ||
| 2 | 10 | 2 | 8 | ||
| unknown | 45 | 15 | 30 | ||
| Primary Site | Renal pelvis | 22 | 8 | 14 | 0.314 |
| Ureter | 22 | 4 | 18 | ||
| Bladder | 50 | 11 | 39 | ||
| Disease presentation | Recurrent | 57 | 13 | 44 | 0.642 |
| Metastatic | 37 | 10 | 27 | ||
| Metastatic site | Lymphnode only | 36 | 10 | 26 | 0.556 |
| Liver, Lung, bone, others | 58 | 13 | 45 | ||
| Regimen | Gem/Cis | 29 | 4 | 25 | 0.108 |
| Gem/Carbo | 65 | 19 | 46 | ||
| previous chemotherapy | No | 83 | 21 | 62 | 1.000 |
| Yes | 11 | 2 | 9 | ||
| Subsequent chemotherapy | No | 43 | 9 | 34 | 0.464 |
| Yes | 51 | 14 | 37 | ||
| Surgery | No | 41 | 13 | 28 | 0.151 |
| Yes | 53 | 10 | 43 | ||
| H-score of APOBEC3B | median (range) | 110 (0–280) | 70 (0–90) | 120 (95–280) | |
* Low: H-score ≤ 90, ** High, H-score > 90, H-score (nucleus + cytoplasm) = intensity × proportion. *** ECOG-PS (0, no performance restrictions; 1, fully ambulatory and able to carry out light work; 2, Up and about >50% of waking hours).